Inovio Must Face Trimmed Investor Claims Over Virus Vaccine
Biotechnology firm Inovio Pharmaceuticals Inc. and a cohort of company executives must face slightly trimmed class action claims alleging they misled the public about a coronavirus vaccine they purport to have...To view the full article, register now.
Already a subscriber? Click here to view full article